研究单位：[1]Shanghai Zhongshan Hospital[2]Anhui Provincial Hospital Hefei, Anhui, China, 230000[3]Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China, 430000华中科技大学同济医学院附属同济医院[4]West China Hospital Chengdu, Sichuan, China, 610000[5]180 Fenglin Road Shanghai, China, 200032
研究目的：
Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in patients with potential resectable HCC and improve the long term survival.
